Finance

Lists
Why is PTGX up २.७३%?
Dive Deeper
PTGX:NASDAQ
Protagonist Therapeutics Inc
US$ १४३.७३
+२.७३%
(+३.८२) 1D
US$ १४३.००
-०.५१% (-०.७३)
After hours
Closed: अक्टोबर ९, १६:००:०० GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTGX...
Open
US$ १३९.९१
High
US$ १४६.३०
Low
US$ १३८.९५
Mkt. cap
९.३० अरब
Avg. vol.
७.१५ लाख
Volume
७.६३ लाख
P/E ratio
१३८.५९
52-wk high
US$ १६०.८१
52-wk low
US$ ६५.७७
EPS
US$ १.०४
Beta
१.५३
Shares outstanding
६.४७ करोड
No. of employees
१४१
Open
US$ १३९.९१
High
US$ १४६.३०
Low
US$ १३८.९५
Mkt. cap
९.३० अरब
Avg. vol.
७.१५ लाख
Volume
७.६३ लाख
P/E ratio
१३८.५९
52-wk high
US$ १६०.८१
52-wk low
US$ ६५.७७
EPS
US$ १.०४
Beta
१.५३
Shares outstanding
६.४७ करोड
No. of employees
१४१
News stories
From web sources and news partners
About Protagonist Therapeutics Inc
CEO-
Employees१४१
Founded२००६
HeadquartersNewark, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 12 analysts giving stock ratings to PTGX in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for PTGX in the last 3 months.
Highest
Current US$ १४३.७३
US$ १८६.०० (+२९.४१%)
Average
US$ १६७.०० (+१६.१९%)
Lowest
US$ १२१.०० (-१५.८१%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
US$ १८२.००
+२६.६%
09/09/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
US$ १८६.००
+२९.४%
08/31/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
US$ १४९.००
+३.७%
08/31/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
09/01/2026
Etzer Darout
Barclays
Buy
Maintained
US$ १८०.००
+२५.२%
08/31/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
US$ १७३.००
+२०.४%
08/31/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
US$ १७०.००
+१८.३%
08/31/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
US$ १७०.००
+१८.३%
09/01/2026
Evan Seigerman
BMO Capital
Buy
Maintained
US$ १७८.००
+२३.८%
08/30/2026
Yun Zhong
Wedbush
Buy
Maintained
US$ १७३.००
+२०.४%
08/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
US$ १५५.००
+७.८%
08/05/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ १२१.००
-१५.८%
07/16/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
US$ ११०.००
-२३.५%
03/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
४७.१२ लाख
७४.३७ लाख
५.६४ करोड
२१.३५ करोड
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
४.०० करोड
४.६४ करोड
४.६७ करोड
४.२१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.११ करोड
१.१४ करोड
१.३३ करोड
१.२६ करोड
Operating expense
५.११ करोड
५.७८ करोड
६.०० करोड
५.४७ करोड
Total operating expenses
५.११ करोड
५.७८ करोड
६.०० करोड
५.४७ करोड
Operating income
-४.६४ करोड
-५.०४ करोड
-३६.४८ लाख
१५.८८ करोड
Other non operating income
-
२७.०० हजार
५३.०० हजार
-८१.०० हजार
EBT including unusual items
-३.९३ करोड
-४.३७ करोड
२२.८१ लाख
१६.५१ करोड
EBT excluding unusual items
-३.९३ करोड
-४.३७ करोड
२२.८१ लाख
१६.५१ करोड
Income tax expense
-
६.६६ लाख
-१५.०२ लाख
२२.६५ लाख
Effective tax rate
-
-१.५२%
-६५.८५%
१.३७%
Other operating expenses
-
-
-
-
Net income
-३.९३ करोड
-४.४४ करोड
३७.८३ लाख
१६.२८ करोड
Net profit margin
-८३४.८७%
-५९६.८०%
६.७१%
७६.२८%
Earnings per share
-०.६२
-०.६९
०.०५
२.२९
Interest and investment income
७०.४९ लाख
६७.६१ लाख
५८.७६ लाख
६४.२९ लाख
Interest expense
-
-
-
-
Net interest expenses
७०.४९ लाख
६७.६१ लाख
५८.७६ लाख
६४.२९ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-४.६१ करोड
-५.०० करोड
-३२.४१ लाख
१५.९२ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू